Garrett DeBernardi

• Led marketing, account management, and sales teams to develop and execute Alzheimer's HCO (Healthcare Organization) launch strategies, delivering 100% to plan performance for Kisunla and Amyvid.
• Effectively recruited, hired, and developed a team of high-performing associates through individual coaching, high accountability, and the development of a vision to go from "exceptional to legendary."
• Effectively collaborated with sales and market access field leadership to develop an evolved cross-functional HCO account management framework and process, doubling Kisunla's performance in priority accounts.
• Led team of direct reports and partnered with commercial learning & development, sales, and market access field leadership to develop training and meeting cycle content for District Sales Managers, Territory Managers, and Account Managers for both National and Regional field meetings.
• Led the development of performance objectives and incentive compensation plans for market access field teams, effectively partnering with cross-functional Analytics and Incentives teams.

• Led the development of a 5-year vision and transformation plan for the US Cardiometabolic Health (US CMH) Business Unit, leveraging perspectives from the internal Corporate Strategy team, an external consulting firm, and the US CMH Executive Leadership Team, delivering above-plan BU performance in year one and on track to exceed 5-year revenue plan goals.
• Led the development and execution of a cross-customer (HCP, Payer, Consumer, & HCO) incretin supply communications strategy during Lilly's incretin portfolio supply shortages, collaborating effectively with legal, manufacturing, marketing, market access, sales, public relations, and the US CMH Executive Leadership team, preserving a positive customer experience, and delivering above-plan incretin portfolio performance amidst supply constraints.
• Led the development of a Senior Director Coaching Curriculum for the US CMH Business Unit, collaborating effectively with Leadership & Development, and the US CMH Executive Leadership Team to improve year-over-year coaching effectiveness scores.
• Acted as a key member of the incretin portfolio strategy team, providing critical input and expertise in the development of a five-year commercial incretin portfolio strategy, delivering above-plan incretin performance in year one, and on track to exceed five-year goals.

• Led marketing, sales, and market access teams to effectively develop and execute Trulicity Specialty and Primary Care strategies, delivering 100% and 104% to plan performance, respectively, in 2022 and 2023.
• Led marketing, sales, and market access teams to effectively develop and execute Trulicity Senior Care strategies, delivering 108% and 131% to plan performance, respectively, in 2022 and 2023.
• Effectively led and developed a team of high-performing associates through individual coaching and high accountability, enabling the delivery of above-brand performance and internal promotions for all associates.
• Effectively partnered with sales leadership, analytics, and incentives teams to set sales field performance objectives, compensation plans, and execute brand strategies.
• Effectively led marketing and sales teams to develop and implement key tactics and resources to deliver above-plan sales performance.
• Effectively partnered with cross-functional marketing, sales leadership, and sales training teams to develop and execute a co-positioning and dual sales messaging strategy to drive continued Trulicity growth and a successful Mounjaro launch, delivering above brand performance for both products.

• Led the development of the 2021 and 2022 cross-functional brand strategy (Customer Plan), effectively collaborating with payer, consumer, and analytics teams to deliver 100% to plan performance in both years.
• Led the development and execution of the Trulicity high-dose HCP launch, delivering 100% to plan performance and stealing 8% SOM from competition.
• Led the development of the cross-functional brand measurement plan, effectively collaborating with payer, consumer, and analytics teams to set and measure performance objectives, and adjusting accordingly.
• Led all sales force execution by partnering closely with sales leadership and territory managers to lead the development, evolution, and implementation of various Salesforce tactics and solutions.
• Partnered closely with sales leadership and training teams to develop training and meeting cycle content for District Sales Managers and Territory Managers.
• Led all non-personal HCP channel execution to supplement sales channel efforts and content, exceeding all non-personal HCP reach and engagement goals by 6% to 10%.

• Rebuilt a diverse and high-performing sales team comprised of 11 territory managers promoting the Lilly Diabetes Portfolio, driving a complete performance turnaround within 6 months (85% to plan; bottom 20% in Q1/Q2 -> 120% to plan; top 20% in Q3/Q4 2018)
• Sustained a healthy, inclusive, and high-performing team culture, delivering consistent performance in 2019 (103.5% to plan; top 20%).
• Effectively developed direct reports, delivering 3 President's Council winners, 2 in-line promotions, and 1 Area and National Territory Manager of the Year.
• Fostered career development for internal talent across the national cross-BU field team by identifying and developing 4Territory Managers into marketing promotions and 1Territory Manager acceptance into the Field-Based Leadership Program.

• Led the development and execution of multiple U.S. market access and launch strategies for CYRAMZA and ERBITUX, delivering disproportionate year-over-year growth (~15%) in key accounts.

• Partnered closely with market access field leadership and account managers in leading the development, evolution, and implementation of all market access field tactics and solutions to drive performance in key HCO accounts.

• Led the development of the cross-functional ERBITUX brand measurement plan, effectively collaborating with payer, consumer, and analytics teams to set and measure performance objectives, and adjusting accordingly.
• Led US ERBITUX and CYRAMZA Payer Value Message Evolution market research projects to develop evolved value and sales force messages for account managers and sales teams.
• Led the development of a Hispanic consumer marketing strategy for the Lilly oral diabetes portfolio.

• Led the execution of successful CYRAMZA and Trulicity trade launches, effectively partnering with marketing, sales, and market access field leadership to support above-plan launch performance for both products.
• Led the development and execution of CYRAMZA’s exclusive Specialty Pharmacy program, effectively collaborating with marketing, sales, and market access leadership to deliver a successful program and above-plan launch performance.

• Promoted the Lilly Musculoskeletal portfolio, driving a complete territory performance turnaround within 6 months (80% to plan; bottom 5% in Q1/Q2 -> 105% to plan; top 20% in Q3/Q4 2010)
• Sustained consistent top territory performance at 105% in 2011 (Top 10%), 115% in 2012 (Top 5%), and 113% in 2013 (Top 10%).
• Successfully launched the Cymbalta chronic pain indication, delivering the #3 launch in the US (132% to goal).
• Successfully launched the Cialis benign prostatic hyperplasia indication, delivering the #5 launch in the US (122% to goal).
• Acted as a key member of the Evista Message Management Team, providing expertise in the evolution of sales messaging strategy and execution to deliver above-plan Evista performance.
• Served as a key coach and mentor to four new sales representatives in the South MSK region.